Urovant Sciences announced the commercial launch of Gemtesa (vibegron) 75 mg tablets for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults
Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has announced the commercial launch of Gemtesa (vibegron) 75 mg tablets, a beta-3… read more.
